292 related articles for article (PubMed ID: 29315500)
1. Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07).
Montemurro M; Cioffi A; Dômont J; Rutkowski P; Roth AD; von Moos R; Inauen R; Toulmonde M; Burkhard RO; Knuesli C; Bauer S; Cassier P; Schwarb H; Le Cesne A; Koeberle D; Bärtschi D; Dietrich D; Biaggi C; Prior J; Leyvraz S
Cancer; 2018 Apr; 124(7):1449-1454. PubMed ID: 29315500
[TBL] [Abstract][Full Text] [Related]
2. Mixed response on regorafenib treatment for GIST (gastro-intestinal stromal tumor) according to
Van Weehaeghe D; Gheysens O; Vandecaveye V; Schöffski P; Van Laere K; Deroose CM
BMC Cancer; 2018 Mar; 18(1):253. PubMed ID: 29506493
[TBL] [Abstract][Full Text] [Related]
3. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
Prior JO; Montemurro M; Orcurto MV; Michielin O; Luthi F; Benhattar J; Guillou L; Elsig V; Stupp R; Delaloye AB; Leyvraz S
J Clin Oncol; 2009 Jan; 27(3):439-45. PubMed ID: 19064982
[TBL] [Abstract][Full Text] [Related]
4. Patterns of extension of gastrointestinal stromal tumors (GIST) treated with imatinib (Gleevec®) by 18F-FDG PET/CT.
Valls-Ferrusola E; García-Garzón JR; Ponce-López A; Soler-Peter M; Fuertes-Cabero S; Moragas-Solanes M; Riera-Gil E; Carrió-Gasset I; Lomeña-Caballero F
Rev Esp Enferm Dig; 2012 Jul; 104(7):360-6. PubMed ID: 22849497
[TBL] [Abstract][Full Text] [Related]
5. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM
Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
[TBL] [Abstract][Full Text] [Related]
6. Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.
Schuetze SM; Bolejack V; Thomas DG; von Mehren M; Patel S; Samuels B; Choy E; D'Amato G; Staddon AP; Ganjoo KN; Chow WA; Rushing DA; Forscher CA; Priebat DA; Loeb DM; Chugh R; Okuno S; Reinke DK; Baker LH
JAMA Oncol; 2018 Jun; 4(6):814-820. PubMed ID: 29710216
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study.
Goldstein D; Tan BS; Rossleigh M; Haindl W; Walker B; Dixon J
Oncology; 2005; 69(4):326-32. PubMed ID: 16293972
[TBL] [Abstract][Full Text] [Related]
8. Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'.
Schöffski P; Mir O; Kasper B; Papai Z; Blay JY; Italiano A; Benson C; Kopeckova K; Ali N; Dileo P; LeCesne A; Menge F; Cousin S; Wardelmann E; Wozniak A; Marreaud S; Litiere S; Zaffaroni F; Nzokirantevye A; Vanden Bempt I; Gelderblom H
Eur J Cancer; 2020 Jul; 134():62-74. PubMed ID: 32470848
[TBL] [Abstract][Full Text] [Related]
9. Assessment of early response to imatinib 800 mg after 400 mg progression by ¹⁸F-fluorodeoxyglucose PET in patients with metastatic gastrointestinal stromal tumors.
Chacón M; Eleta M; Espindola AR; Roca E; Méndez G; Rojo S; Pupareli C
Future Oncol; 2015; 11(6):953-64. PubMed ID: 25760976
[TBL] [Abstract][Full Text] [Related]
10. Performance of F-18 FDG PET/CT for predicting malignant potential of gastrointestinal stromal tumors: A systematic review and meta-analysis.
Kim SJ; Lee SW
J Gastroenterol Hepatol; 2018 Mar; 33(3):576-582. PubMed ID: 28994187
[TBL] [Abstract][Full Text] [Related]
11. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
[TBL] [Abstract][Full Text] [Related]
12. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
Choi H; Charnsangavej C; Faria SC; Macapinlac HA; Burgess MA; Patel SR; Chen LL; Podoloff DA; Benjamin RS
J Clin Oncol; 2007 May; 25(13):1753-9. PubMed ID: 17470865
[TBL] [Abstract][Full Text] [Related]
13.
Altini C; Mammucci P; Pisani AR; D'Alò C; Sardaro A; Rubini D; Ferrari C; Rubini G
Hell J Nucl Med; 2021; 24(3):239-246. PubMed ID: 34901964
[TBL] [Abstract][Full Text] [Related]
14. Multimodal functional imaging for early response assessment in patients with gastrointestinal stromal tumor treated with tyrosine kinase inhibitors.
Revheim ME; Hole KH; Mo T; Bruland ØS; Reitan E; Julsrud L; Seierstad T
Acta Radiol; 2022 Aug; 63(8):995-1004. PubMed ID: 34171968
[TBL] [Abstract][Full Text] [Related]
15. Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib.
Kim JJ; Ryu MH; Yoo C; Beck MY; Ma JE; Kang YK
Oncologist; 2019 Nov; 24(11):e1212-e1218. PubMed ID: 31036770
[TBL] [Abstract][Full Text] [Related]
16. Early Evaluation of Response Using
Farag S; Geus-Oei LF; van der Graaf WT; van Coevorden F; Grunhagen D; Reyners AKL; Boonstra PA; Desar I; Gelderblom H; Steeghs N
J Nucl Med; 2018 Feb; 59(2):194-196. PubMed ID: 28970330
[No Abstract] [Full Text] [Related]
17. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET.
Jager PL; Gietema JA; van der Graaf WT
Nucl Med Commun; 2004 May; 25(5):433-8. PubMed ID: 15100500
[TBL] [Abstract][Full Text] [Related]
18. The value of (18) F-fluorodeoxyglucose positron emission tomography for prediction of treatment response in gastrointestinal stromal tumors: a systematic review and meta-analysis.
Hassanzadeh-Rad A; Yousefifard M; Katal S; Asady H; Fard-Esfahani A; Moghadas Jafari A; Hosseini M
J Gastroenterol Hepatol; 2016 May; 31(5):929-35. PubMed ID: 26642423
[TBL] [Abstract][Full Text] [Related]
19. Diffusion-weighted magnetic resonance imaging in metastatic gastrointestinal stromal tumor (GIST): a pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CT.
Schmidt S; Dunet V; Koehli M; Montemurro M; Meuli R; Prior JO
Acta Radiol; 2013 Oct; 54(8):837-42. PubMed ID: 23761549
[TBL] [Abstract][Full Text] [Related]
20. [Role of FDG PET in the staging, recurrence and treatment response to imatinib (Glivec) in patients with gastrointestinal stromal tumors].
Simó Perdigó M; García Garzón JR; Soler Peter M; Pérez Moure G; López Gandul S; Lomeña Caballero FJ
Rev Esp Med Nucl; 2006; 25(2):80-8. PubMed ID: 16759613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
